ÔÚÃâÒßѧ¡¢Ñ¬È¾²¡¡¢°©Ö¢ÉúÎïѧ¡¢ÔìѪ¸Éϸ°ûºÍÔÙÉúҽѧµÈÁìÓòµÄÑо¿ÖУ¬ÃâÒßȱÏÝСÊóÒѾ³ÉΪʮ·ÖÖ÷ÒªµÄÄ£×Ó¹¤¾ß¡£µ«ÏÖÔÚÃâÒßȱÏÝСÊóµÄƷϵ·±¶à£¬ÇÒÿÖÖƷϵ×ÔÉíÌØÕ÷Ò²ÓÐËù²î±ð¡£ÎÒÃÇÔõÑùÑ¡ÔñºÏÊʵÄÃâÒßȱÏÝСÊóÄ£×ÓÄØ£¿
±¾ÆÚС±à½«¶ÔÃâÒßȱÏÝСÊó¾ÙÐÐÖÜÈ«ÅÌ»õ¡£
ÃâÒßȱÏÝСÊóÉú³¤ÀúÊ·
ͼ1. ÃâÒßȱÏÝÊóÉú³¤Ê·[1]
×ÔÉÏÊÀ¼Í60ÄêÔ£¬ÂãÊó×÷ΪµÚÒ»ÀàÃâÒßȱÏÝƷϵ·ºÆðÒÔÀ´£¬ÃâÒßȱÏÝСÊóÉú³¤ÖÁ½ñÒÑÓÐ80¶àÄêµÄÀúÊ·¡£ÔÚÕâÂþ³¤µÄÀú³ÌÖУ¬Ò»Ö±·ºÆðÖÖÖÖеÄƷϵ£¬ÎÒÃǶÔÃâÒßȱÏÝСÊóµÄÑо¿Ò²Óú·¢ÉîÈ룬ÏÂÃæС±à½«ÎªÄãÏÈÈÝһϳ£¼ûƷϵµÄÉú³¤Àú³Ì¡£
ÂãÊó
1962Ä꣬ÔÚÓ¢¹ú¸ñÀ˹¸çRuchillÒ½ÔºµÄ²¡¶¾ÊµÑéÊÒÖУ¬²¡¶¾Ê¢Ðв¡Ñ§¼ÒNorman Grist¡°Å¼ÓöÁË¡±Ò»Ö»È«ÉíÎÞëµÄСÊó£¬ÕâֻСÊó¾ÍÊǵÚÒ»Ö»±»·¢Ã÷µÄÂãÊó¡£
ͼ2. a£º´ÆÐÔÂãÊ󴿺Ï×Ó£¨nu/nu£©£¬b£º´ÆÐÔÂãÊóÔÓºÏ×Ó£¨nu/+)[2]
ÂãÊóµÄÖ÷ÒªÌØÕ÷ÌåÏÖΪÎÞ루Hairless£©ºÍÎÞÐØÏÙ£¨Athymus£©¡£ÕâЩ±íÐ͹é×ïÓÚFoxn1ÂÑ°×µÄÒþÐÎÍ»±ä¡£ÎÞëµÄ³ÉÒò²¢²»ÊÇëÄÒȱʧ£¬¶øÊÇÓÉÓÚFoxn1¹¦Ð§È±Ê§µ¼ÖÂë·¢ÎÞ·¨´©Í¸±íƤ£¬ÅÌÈÆÔÚ»ùµ×²ãÄÚ¡£¶øСÊóÎÞÐØÏÙͬÑùÊÇÓÉÓÚFoxn1¹¦Ð§È±Ê§£¬µ¼ÖÂÐØÏÙÉÏƤϸ°ûºÍTϸ°û×æϸ°ûÎÞ·¨Õý³£ÔöÖ³ºÍ·Ö½â£¬Ó°ÏìÐØÏٵķ¢ÓýºÍ³ÉÊì¡£
ͼ3. ÂãÊó뱬·¢³¤Ê¾Òâͼ
ͼ4. ÐØÏÙÉÏƤϸ°ûµ÷¿ØTϸ°û×æϸ°û·Ö½â
ÏÖÔÚ£¬ÂãÊóÖ÷ÒªÓÃ×÷¹¹½¨Ö×ÁöµÄÒìÔ´ÒÆֲģ×Ó¡£Æ¾Ö¤ÒÆֲȪԴ²î±ð·ÖΪCDXºÍPDXÄ£×Ó¡£µ«ÓÉÓÚÂãÊóÖ»±£´æTϸ°ûÃâÒßȱÏÝ£¬Ö×ÁöÒÆÖ²ÖÖÀàÖ»ÏÞÓÚʵÌåÁö£¬²¢ÇÒ³ÉÁöÂÊ¡¢Ö×ÁöÉú³¤ºÍתÒƶ¼»áÊܵ½ÏÞÖÆ¡£
ÓÉÓÚÂãÊóµÄÈéÏÙ·¢Óý²»ÍêÈ«£¬ÂãÊóµÄ·±Óý·½·¨Ö÷ÒªÊÇͨ¹ý´ÆÐÔÔÓºÏ×ÓºÍÐÛÐÔ´¿ºÏ×Ó¾ÙÐн»Åä¡£
ÄÏÄ£ÉúÎïºã¾ÃÌṩÏÖ»õÂãÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊBALB/c NudeСÊó¾ÙÐÐ×Éѯ¡£
SCIDСÊó
1983Ä꣬Bosma£¨ÃÀ¹úFox Chase°©Ö¢Ñо¿Ëù£©ÔÚCB17½ü½»ÏµÐ¡ÊóÖз¢Ã÷λÓÚ16ºÅȾɫÌåÉϵÄPrkdc»ùÒò±£´æÒþÐÔÍ»±ä£¬²¢Ê×´ÎÐÎòÁËȱ·¦¹¦Ð§ÐÔTºÍBÁÜ°Íϸ°ûµÄÑÏÖØÍŽáÃâÒßȱÏÝ£¨Severe Combined Immunodeficient Mice£¬SCID£©Ð¡Êó¡£
SCIDСÊóÍâ¹ÛÓëÆÕ±éСÊóÎÞ²î±ð£¬ÌåÖØ·¢ÓýÕý³££¬ÃâÒßϸ°û·¢Óý·Ö½âÇéÐÎÕý³££¬µ«ÐØÏÙ¡¢Æ¢Ôà¡¢ÁÜͶºÏµÈ×éÖ¯Æ÷¹ÙÖÐÎÞ¹¦Ð§ÐÔTϸ°û¼°Bϸ°û¡£Prkdc»ùÒò±àÂëÁËDNAÒÀÀµÐÔÂÑ°×¼¤Ã¸µÄ´ß»¯ÑÇ»ù£¨DNA-PKcs£©¡£¸ÃÂÑ°×ÊÇDNAÐÞ¸´ÖÐNHEJͨ·µÄÒªº¦ÂÑ°×£¬²¢ÇÒ¼ÓÈëÁËT¡¢B ϸ°ûµÄ T ϸ°û¿¹ÔÊÜÌ壨TCR£©¡¢B ϸ°û¿¹ÔÊÜÌ壨BCR£©»ùÒòµÄV(D)JÖØÅÅ¡£SCIDСÊóPrkdcµÄȱʧµ¼ÖÂTCR¡¢BCR»ùÒòµÄV(D)JÖØÅÅÎÞ·¨¾ÙÐУ¬½ø¶øÓ°ÏìT¡¢Bϸ°ûµÄ³ÉÊì¡£
ͼ6. µä·¶DNAË«Á´¶ÏÁѵÄÐÞ¸´Í¾¾¶[3]
ÓëÂãÊóÏà±È£¬SCIDСÊóµÄÈËÀàÖ×ÁöÖ²ÈëЧÂʸü¸ß¡£SCIDСÊóµÄÃâÒßϸ°û·¢Óý·Ö½âÇéÐÎÕý³££¬ÀíÂÛÉÏ¿ÉÒÔÓÃ×÷ÈËÔìѪ¸Éϸ°û£¨HSCs£©ºÍÍâÖÜѪµ¥ºËϸ°û£¨PBMC£©ÒÆÖ²µÄÊÜÌ壬µ«ÒÆֲЧÂʲ¢²»²ÇÏë¡£ÕâÊÇÓÉÓÚSCIDСÊóÊ£ÓàÓÐNKϸ°û¡¢²¹Ìå¼°Ëèϵϸ°ûµÄÕý³£ÃâÒߣ¬×èÖ¹ÁËÈËÀàϸ°ûµÄ¹é³²ºÍά³Ö¡£±ðµÄ£¬ÓÉÓÚPrkdcµÄȱʧ£¬SCIDСÊó¶Ô·øÕÕ½ÏΪÃô¸Ð£¬ÎÞ·¨ÔÚÒÆֲǰ¾ÙÐзøÕÕ´¦Öóͷ£¡£Ëæ×ÅÄêËêµÄÔöÌí£¬SCIDСÊó»á±¬·¢ÃâÒßϸ°ûй¶£¬±¬·¢Ò»¶¨Ë®Æ½µÄ¹¦Ð§ÐÔT¡¢Bϸ°û¡£
RAG-/-СÊó£¨ÖØ×鼤»î»ùÒòȱʧСÊó£©
1992Ä꣬ȱʧÖØ×鼤»î»ùÒò£¨Rag-/-£©µÄÃâÒßȱÏÝСÊóÄ£×ÓÎÊÊÀ¡£ÖØ×鼤»î»ùÒò°üÀ¨ Rag1 ºÍ Rag2 £¬Á½Õß±àÂëµÄRAG1ºÍRAG2×é³ÉµÄRAG¸´ºÏÌåÔÚTCRºÍÃâÒßÇòÂÑ°× V(D)JÖØÅÅÖÐÆðµ½Òªº¦×÷Óá£RAG¸´ºÏÌåʶ±ðRSSÐòÁв¢½«DNAË«Á´¼ôÇУ¬Ö®ºó DNA Ë«Á´Í¨¹ý DNA-PKcs¡¢Ku70/Ku80¡¢ArtemisµÈøÆô¶¯NHEJ£¬ÐÞ¸´DNAË«Á´Íê³É VDJ ÖØÅÅ¡£Òò´Ë£¬Rag1ºÍ Rag2 ÈÎÒ»»ùÒòµÄȱʧ¶¼»áµ¼ÖÂTϸ°ûºÍBϸ°ûµÄȱ·¦¡£
ͼ7. VDJÖØÅÅʾÒâͼ[4]
Rag1-/-ºÍRag2-/-СÊóµÄÌØÕ÷»ùÄÚÇéËÆ¡£ÓëSCIDСÊóÏà±È£¬Rag»ùÒòȱʧÄܸüÔçÇÒ¸üÍêÈ«µØ×è¶ÏTºÍBϸ°û·Ö½â¡£²¢ÇÒRag»ùÒòȱʧ²»Ó°ÏìDNAË«Á´ÐÞ¸´Àú³Ì£¬Òò´ËRag-/-СÊó¶Ô·øÕÕ²»Ãô¸Ð¡£²»¹ý£¬Rag-/-СÊó±£´æÁ˽ϸßˮƽµÄNKϸ°û£¬ÔÚÒ»¶¨Ë®Æ½ÉÏÒ²ÏÞÖÆÁËÈËHSCϸ°ûµÄÒÆÖ²¡£
ÄÏÄ£ÉúÎïÌṩRag-KOСÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊRag-KOСÊó¾ÙÐÐ×Éѯ¡£
NOD-SCIDСÊó
ÎÞÂÛÊÇSCIDСÊóÕÕ¾ÉRag KOСÊó£¬ÓÉÓÚÆä¹ÌÓÐÃâÒß»îÐÔÏÞÖÆÁËÈËÀà×é֯ϸ°ûµÄ¶¨Ö²ÂÊ¡£Òò´Ë£¬¿Æѧ¼ÒÃÇʵÑéͨ¹ýÌ滻СÊóÅä¾°¸Ä±äÕâÒ»ÇéÐΡ£NOD SCIDСÊóÓ¦Ô˶øÉú¡£
1980Ä꣬ Makino£¨ÈÕ±¾Shionogi¹«Ë¾£©·¢Ã÷·Ç·ÊÅÖÌÇÄò²¡£¨NOD£©Ð¡Êó»¼ÓÐÓÉTÁÜ°Íϸ°û½þÈóºÍÒȵº¦Âϸ°ûÆÆËðÒýÆðµÄÌÇÄò²¡£¬Í¬Ê±»¹°éÓжàÖÖÃâÒßÒì³££¬°üÀ¨²¹ÌåȱʧºÍNK¡¢¾ÞÊÉϸ°ûºÍÊ÷ͻ״ϸ°û¹¦Ð§ÊÜËðµÈ¡£
ͼ8. NODСÊóÃâÒßÒ쳣ϸ°û
1995Ä꣬Shultzͨ¹ýÔÓ½»NODºÍSCIDСÊó½¨ÉèÁËNOD SCIDСÊó¡£NOD SCIDСÊ󲻻ᱬ·¢ÌÇÄò²¡£¬È±·¦Tϸ°ûºÍBϸ°û£¬»¼ÓеͱûÖÖÇòÂÑ°×Ѫ֢£¬²¹Ìå»îÐÔ½µµÍ£¬¿¹Ô³ÊµÝϸ°û£¨APC£©¡¢¾ÞÊÉϸ°ûºÍNKϸ°ûµÄ¹¦Ð§Êܵ½Ë𺦡£Òò´Ë³ÉΪÈËÀàÔìѪ¸Éϸ°ûºÍÈËÀàʵÌåÁöÒÆÖ²µÄ¸üºÃµÄÊÜÌå¡£±ðµÄ£¬ShultzµÈÑо¿·¢Ã÷£¬SCIDСÊóÃâÒßÉø©¸ß´ï90%£¬¶øNOD SCIDСÊóÔòµÍÓÚ10%¡£NOD SCIDСÊóÒ»¶È³ÉΪÔìѪϸ°ûÑо¿ÖÐÓ¦ÓÃ×î¹ã¡¢×îΪÖ÷ÒªµÄÒÆֲģ×Ó¡£
ÄÏÄ£ÉúÎïºã¾ÃÌṩÏÖ»õNOD SCIDСÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊNOD SCIDСÊó¾ÙÐÐ×Éѯ¡£
IL2rg-/-СÊó
XÁ¬ËøÖØ֢͎áÃâÒßȱÏÝÖ¢£¨X-SCID£©ÊÇÒ»ÖÖ X ȾɫÌåÒþÐÔÒÅ´«µÄÃâÒßȱÏݲ¡£¬ÌåÏÖΪÍâÖÜѪTϸ°ûºÍNKϸ°ûµÄȱ·¦£¬Bϸ°ûͨ³£±£´æµ«ÏÕЩûÓÐÃâÒßÇòÂѰס£X-SCIDÊÇÓÉIL2RG »ùÒòÍ»±äÒýÆðµÄ£¬¸Ã»ùÒò±àÂë×ÌÈÅ°×ϸ°û½éËØ2£¨interleukin2, IL-2£©ÊÜÌågammaÁ´£¨IL-2R¦Ãc£©¡£
ͼ9. X-SCID¼²²¡»¼Õß
IL-2R¦ÃcÊÇÐγɸßÇ׺ÍÁ¦ÊÜÌåµÄÖ÷Òª×é³É²¿·Ö£¬ÄܱàÂëÖ÷ÒªµÄÐźÅͨ·×é³ÉÒò×Ó£¨Èçϸ°ûÒò×ÓIL-2¡¢IL-4¡¢IL-7¡¢IL-9¡¢IL-15ºÍIL-21£©£¬Õâ¹ØÓÚÁÜ°Íϸ°ûºÍNKϸ°ûµÄ·¢ÓýÖÁ¹ØÖ÷Òª¡£
ͼ10. IL-2R¦ÃcÏà¹Øϸ°ûÒò×Ó[5]
1995Ä꣬ͨ¹ý°ÐÏòÇóýIL2rg»ùÒò£¬»ñµÃÁËIL2rg-/-СÊó¡£ËüÃǵÄTϸ°ûºÍBϸ°û·¢ÓýºÍ¹¦Ð§ÑÏÖØÊÜËð£¬ÇÒNKϸ°û·¢Óý±»ÍêÈ«×è¶Ï¡£IL2rg-/-СÊóµÄ±¬·¢Ê¹¸ü¶à¹ÌÓÐÃâÒßȱÏÝСÊóÄ£×Ó³ÉΪ¿ÉÄÜ£¬¿ÉÒÔ´ó´ó½µµÍÈËÌåϸ°ûºÍ×éÖ¯µÄÇãÔþÂÊ¡£
IL-2R¦ÃÓëJak3¼¤Ã¸Ï໥×÷ÓþÙÐÐÐźÅתµ¼£¬Òò´Ë£¬Jak3ȱʧµÄJak3-/-СÊóÓëIL2rg-/-СÊóÀàËÆ£¬Ò²È±·¦NKϸ°ûÇÒT¡¢BÁÜ°Íϸ°ûïÔÌ¡£
ÄÏÄ£ÉúÎïÌṩIL2rg-KOСÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊIl2rg-KOСÊó¾ÙÐÐ×Éѯ¡£
M-NSGСÊó
IL2rgȱÏÝСÊó£¬ÎªÃâÒßȱÏÝСÊóƷϵµÄ¹¹½¨ÌṩÁËеÄ˼Ð÷¡£¸÷µØ¿Æѧ¼ÒÃÇ·×·×ʵÑ齫IL2rgȱÏÝÒýÈëNOD SCIDСÊ󣬹¹½¨ÃâÒßȱÏÝˮƽ¸ü¸ßµÄСÊó¡£ÄÏÄ£ÉúÎïÔÚNOD SCIDСÊóÖÐÇóýIl2rg»ùÒò£¬Àֳɹ¹½¨³öÁËM-NSGСÊó¡£
M-NSGȱ·¦³ÉÊìµÄ T¡¢B ºÍ NK ϸ°û£¬¶ÔÈËԴϸ°ûºÍ×éÖ¯ÃâÒßÇãÔþ·´Ó¦µÍ£¬Ö×Áöϸ°û³ÉÁöÐԺã¬ÊÇÈËÔ´»¯Ð¡Êó¡¢ÒìÖÖÒÆÖ²¡¢ÃâÒßÖØÐÞµÄÖ÷ÒªÔØÌ壻¹ØÓÚÑо¿ÈËÀàÔìѪ¸Éϸ°û¡¢Ö×Áö±¬·¢ÓëÖÎÁÆ¡¢ÃâÒßȱÏݼ²²¡ÓëÌåÄÚÃâÒß»úÖÆÑо¿¶¼¾ßÓÐÖ÷ÒªÒâÒå¡£
ÓëM-NSGСÊóÏàËƵÄСÊóƷϵÓÐNOGºÍNSGµÈ£¬»®·ÖÊÇÔÚ02ÄêºÍ05ÄêÓÉÈÕ±¾ÊµÑéÊÒºÍÃÀ¹úʵÑéÊÒ¹¹½¨¡£NOGСÊóµÄIL2rgȱ·¦°ûÄڽṹÓò£¬¶øNSGСÊóÔòÍêȫȱʧIL-2rg£¬¶þÕßµÄÃâÒßȱÏÝˮƽÓëM-NSGÏàͬ£¬¶¼ÌåÏÖ³öÁËÎÞ³ÉÊìTϸ°û¡¢Bϸ°ûºÍ¹¦Ð§ÐÔNKϸ°û£¬Ï¸°ûÒò×ÓÐźÅת´ïÄÜÁ¦È±Ê§µÈ¡£
ÄÏÄ£ÉúÎïÌṩM-NSGСÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊM-NSGСÊó¾ÙÐÐ×Éѯ¡£
NRG/BRGµÈÆäËûÏàËÆƷϵ
ÔÚNSGСÊóµÄ»ù´¡ÉÏ£¬¸ü¶àÀàËƵÄÖضÈÃâÒßȱÏÝСÊóƷϵ±»¿ª·¢¡£ÆäÖÐÓ¦ÓÃ×îΪÆÕ±éƷϵµÄÓÐNRGСÊó£¨NOD-Rag1-/- IL2rg-/-£©ºÍBRGСÊó£¨BALB/cA-Rag2-/- IL2rg-/-£©¡£
NRGСÊóÓëNSGСÊóºÜÊÇÀàËÆ£¬ÊÇÓÉRag1»ùÒòȱʧȡ´úscidÍ»±ä£¬¿ÉÒÔսʤscidÍ»±äÒýÆðµÄһЩȱ·¦£¬È磺¶Ô·øÕÕÃô¸Ð¡£BRGСÊóÊÇÔÚBALB/cÅä¾°µÄСÊóÖÐÒýÈëRag1-/-»òRag2-/-Í»±äºÍIL-2R¦Ãȱʧ£¬ÌåÏÖΪT¡¢Bϸ°ûȱʧºÍNKϸ°ûÎÞ»îÐÔ¡£
NRGСÊóµÄÈËHSCϸ°û¶¨Ö²ÂʱÈBRG¸ß£¬Ö÷ÒªµÄÔµ¹ÊÔÓÉÊÇNODСÊó¹ÇËèÖеľÞÊÉϸ°ûÖеÄÐźŵ÷¿ØÂÑ°×alpha(SIRP¦Á)±¬·¢Í»±ä¡£SIRP¦ÁÊÇÒ»ÖÖ¿çĤÂÑ°×£¬ÔÚ¾ÞÊÉϸ°ûÉϱí´ï£¬²¢ÓëÆäÅäÌå CD47ÍŽᡣSIRP¦ÁÓëCD47ÍŽáºó£¬»áÏò¾ÞÊÉϸ°û·¢³öÒÖÖÆÐźţ¬×èÖ¹Æä¾ÙÐÐ×ÔÊÉÔ˶¯£º¼´ËùνµÄ "±ð³ÔÎÒ "Ðźš£ÕâÖÖÍŽá¾ßÓÐÎïÖÖÌØÒìÐÔ¡£ÔÚ´ó´ó¶¼Ð¡ÊóƷϵÖУ¬Ð¡ÊóµÄSIRP¦ÁÎÞ·¨Ê¶±ðÈËÀàµÄCD47£¬´Ó¶øµ¼ÖÂСÊó¾ÞÊÉϸ°ûµÄ»î»¯ºÍ¶ÔÒÆÖ²ÈËÀà×éÖ¯µÄÇãÔþ¡£¶øÍ»±äµÄNODСÊóµÄSIRP¦Á¿ÉÒÔÍŽáÈËÔ´CD47£¬ÒÖÖƾÞÊÉϸ°û¶ÔÈËԴϸ°ûµÄÍÌÊÉ×÷Óá£ÏÖÔÚÒ²Óв¿·Ö¿Æѧ¼Ò½«BRGСÊóµÄSIRP¦Á¾ÙÐÐË¢ÐÂÀ´Ìá¸ßBRGСÊóµÄÈËHSCϸ°û¶¨Ö²ÂÊ¡£
ͼ11. ²î±ðÅ侰СÊóSIRP¦ÁÓëhCD47Ç׺ÍÁ¦±ÈÕÕ[6]
ÄÏÄ£ÉúÎïÌṩBRGСÊó³öÊÛ£¬ÈôÓÐÐèÒª£¬¿É²¦´ò400-728-0660µç»°»òÔÚ¹ÙÍøÅÌÎÊRag2/IL2rg-KO(BALB/c) СÊó¾ÙÐÐ×Éѯ¡£
ÔõÑùÑ¡ÔñÃâÒßȱÏÝСÊó£¿
¶àÖÖ¶àÑùµÄÃâÒßȱÏÝСÊóÈÃÎÒÃÇÔÚ²î±ðµÄÑо¿ÁìÓò»òÑо¿Õ½ÂÔÖпÉÒÔÎÞаѡÔñ£¬ÕâʱÐèÒª´ÓÒÔϼ¸¸ö·½ÃæÀ´×ۺϿ¼Á¿£º
ÒÅ´«Åä¾°
СÊóµÄÒÅ´«Åä¾°£¬ºÃ±È²î±ðÅä¾°µÄСÊóH2µ¥ÌåÐͲî±ð£ºÂãÊó¾ÍÓÐ3ÖÖ²î±ðµÄÅä¾°£ºBALB/c Nude¡¢Nu/Nu¡¢CD-1 Nude¡£ÆäÖÐBALB/c NudeΪ½ü½»Ïµ£¬¸öÌå²î±ðС£¬×î³£ÓÃÓÚÒìÖÖÒÆÖ²ÁöÄ£×ӵĽ¨É裬³ÉÁöËùÐèÖ×Áöϸ°û½ÓÖÖÁ¿ÒÔ¼°³ÉÁöËÙÂʽϺóÁ½ÕßÒ²¶¼¾ßÓÐÒ»¶¨µÄÓÅÊÆ£»Nu/NuºÍCD-1 NudeΪ¹Ø±ÕȺ£¬¸öÌå²î±ð½Ï´ó£¬µ«ÉúÃüÁ¦¸üÐËÍú¡£
ÃâÒßϵͳ×é³ÉÒòËØ
T ÁÜ°Íϸ°û¹¦Ð§È±ÏÝ£¬ÀýÈ磺ÂãÊó
B ÁÜ°Íϸ°û¹¦Ð§È±ÏÝ£¬ÀýÈ磺CBA/NСÊó¡£
NKϸ°û¹¦Ð§È±ÏÝ£¬ÀýÈ磺BeigeСÊó¡£
ÍŽáÃâÒßȱÏÝ£¬ÀýÈ磺NOD-ScidСÊó¡¢NSGСÊóµÈ¡£
Í»±ä»ùÒòÔÚÑо¿Àú³ÌÖУ¬Ë¼Á¿Ä³¸ö»òij¼¸¸ö»ùÒòµÄÍ»±ä¶ÔÃâÒß·´Ó¦µÄÓ°Ï죨ÈçNKϸ°û£¬¾ÞÊÉϸ°ûºÍ²¹Ìå»îÐԵȣ©£¬ÒÔ¼°ÓëÒÅ´«Åä¾°¿ÉÄܵÄÏ໥×÷Óá£ÀýÈ磬¦Â2΢ÇòÂÑ°×£¨B2m£©ºÍ´©¿×ËØ£¨Prf1£©Í»±ä»á½µµÍNKϸ°û»îÐÔ£»°×½éËØ2ÊÜÌå¦ÃÁ´£¨Il2rg£©Í»±äÔòʹNKϸ°ûÍêȫʧ»î£»scidÍ»±äÔÚNODСÊóÖжԿ¹ÌÇÄò²¡µÄ±¬·¢¡£
ÃâÒßϸ°ûµÄ×ß©
ÓеÄÃâÒßȱÏÝСÊóƷϵ»áËæ×ÅÄêËêµÄÔöÌí£¬»á±¬·¢Ò»¶¨Ë®Æ½µÄ¹¦Ð§T¡¢Bϸ°û£¬ÀýÈçSCIDСÊóÃâÒßÉø©¸ß´ï90%¡£
ÊÙÃü
ÓеÄÃâÒßȱÏÝСÊó»á×Ô¾õÁÜ°ÍÁö£¬µ¼ÖÂСÊóÊÙÃü´ó·ùËõ¶Ì£¬Òò´Ëµ¹ÔËÓÚºã¾ÃµÄ¸ú×ÙʵÑé¡£ºÃ±È£ºNod-ScidСÊóµÄÊÙÃüԼĪֻÓÐ8-9¸öÔ¡£
·øÕÕÃô¸Ð¶È
¶Ô·øÕÕÌØÊâÃô¸ÐµÄÃâÒßȱÏÝСÊóƷϵ²»ÊʺÏÔÚÒÆֲǰ¾ÙÐзøÕÕ´¦Öóͷ££¬ºÃ±È£ºscidÍ»±äСÊóµÄ·øÕÕÄÍÊÜÁ¿²»Áè¼Ý400cGy (4 Gy)¡£
×ÌÉúÄÜÁ¦
ÀýÈ磺´ÆÐÔÂãÊóµÄ×ÌÉúÄÜÁ¦ºÜ²î£¬Ö»ÓÐ2.5ÔÂÁäµ½4ÔÂÁäµÄ´ÆÊó²ÅÓÐÉúÓýÄÜÁ¦¡£ÒÔÊÇÂãÊóµÄ·±ÓýÊÇͨ¹ýÐÛÐÔ´¿ºÏ×ÓÓë´ÆÐÔÔÓºÏ×ÓÀ´Íê³ÉµÄ¡£
ÏÈÈÝÁËÕâô¶à£¬ÐÅÍи÷ÈËÒѾÆðÔ´ÕÆÎÕÃâÒßȱÏÝСÊóµÄÏà¹Ø֪ʶ¡£ÃâÒßȱÏÝСÊóÒ»Ö±±¸ÊܹØ×¢£¬ÆäÔÚÖ×ÁöÄ£×Ó¹¹½¨¼°ÈËÔ´»¯ÃâÒßϵͳÖØÐ޵ȷ½ÃæÓÐ×ÅÆÕ±éÓ¦Óã¬ÊǼ²²¡Ïà¹Ø»úÀíÑо¿¡¢ÁÙ´²Ç°Ò©Îïɸѡ¡¢Ò©Ð§Ñ§ºÍÇå¾²ÐÔÆÀ¼ÛµÄÖ÷ÒªÔØÌå¡£
Reference:
[1] Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118-130. doi:10.1038/nri2017
[2] Szadvari I, Krizanova O, Babula P. Athymic nude mice as an experimental model for cancer treatment. Physiol Res. 2016;65(Suppl 4):S441-S453. doi:10.33549/physiolres.933526
[3] Yue X, Bai C, Xie D, Ma T, Zhou PK. DNA-PKcs: A Multi-Faceted Player in DNA Damage Response. Front Genet. 2020;11:607428. Published 2020 Dec 23. doi:10.3389/fgene.2020.607428
[4] Soulas-Sprauel P, Rivera-Munoz P, Malivert L, et al. V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining. Oncogene. 2007;26(56):7780-7791. doi:10.1038/sj.onc.1210875
[5] Spolski R., Gromer D., Leonard W.J. The ¦Ã c family of cytokines: fine-tuning signals from IL-2 and IL-21 in the regulation of the immune response. F1000Res 23;6:1872(2017).
[6] Kwong LS, Brown MH, Barclay AN, Hatherley D. Signal-regulatory protein ¦Á from the NOD mouse binds human CD47 with an exceptionally high affinity-- implications for engraftment of human cells. Immunology. 2014;143(1):61-67. doi:10.1111/imm.12290